# Mologic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mologic

- Industry: Biotechnology
- Headquarters: UK
- Website: www.mologic.co.uk
- Total disclosed funding: $4.5M
- Latest round: Series B (Apr 23, 2018)
- Investors on record: 2

## About

Mologic Ltd., based in the UK, specializes in the development of innovative lateral flow immunoassays for rapid point-of-care diagnostics, addressing critical health needs across various sectors.Founded in 2003, Mologic Ltd. focuses on providing advanced diagnostic solutions. The company was acquired by Global Access Health in July 2021 for approximately GBP 30 million from Calculus Capital and Foresight Group, which yielded significant returns for the investors. Paul Davis is the founder, and Mark Davis currently serves as CEO.Mologic Ltd., through its Global Access Diagnostics (GADx) division, specializes in developing lateral flow immunoassays offering services such as assay design, antibody engineering, validation, and clinical studies. Their solutions aim to meet health needs in human health, veterinary, and agricultural sectors, particularly focusing on infectious diseases and immune-inflammatory conditions, delivered to clients in low- and middle-income countries.In the most recent financial year 2023, Mologic Ltd. reported a revenue of GBP 5,036,849.30 and an EBITDA amount of GBP -703,787.20, indicating the company's current financial status.Following its acquisition in July 2021, Mologic Ltd. is positioned to enhance global diagnostics access in underprivileged regions, utilizing the GBP 30 million from the acquisition to facilitate decentralized research and development. The company aims to expand its operations into additional markets within the Global South, focusing on innovative product development and local manufacturing partnerships to meet regional health needs.

## Funding rounds

- Series B, Apr 23, 2018, $4.5M — Foresight Group, Calculus Capital

## Investors

- Foresight Group (https://capitalatlas.ai/funds/foresight-group) — Series B
- Calculus Capital (https://capitalatlas.ai/funds/calculus-capital) — Series B